Protagenic Therapeutics, Inc.\new Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price
Protagenic Therapeutics, Inc.\new (PTIX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price of $2.12 per share for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-14.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice · last filed 2022-11-14
- Protagenic Therapeutics, Inc.\new share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2022-03-31 was $5.60, a 460.00% increase year-over-year.
- Protagenic Therapeutics, Inc.\new share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2021-03-31 was $1.00.
- Protagenic Therapeutics, Inc.\new share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2021 was $1.00.
- Protagenic Therapeutics, Inc.\new share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2019 was $1.75.
- Protagenic Therapeutics, Inc.\new share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2017 was $1.00, a 284.62% increase from fiscal 2016.
- Protagenic Therapeutics, Inc.\new share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2016 was $0.26.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2022-09-30 | $2.12 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | $2.12 10-Q · filed 2022-08-11 | |||
| 2022-03-31 | $5.60 10-Q · filed 2022-05-13 | |||
| 2021-12-31 | $1.00 10-K · filed 2022-04-07 | |||
| 2021-09-30 | $1.00 10-Q · filed 2021-11-15 | |||
| 2021-06-30 | $1.00 10-Q · filed 2021-08-16 | |||
| 2021-03-31 | $1.00 10-Q · filed 2021-05-17 | |||
| 2019-12-31 | $1.75 10-K · filed 2021-03-25 | |||
| 2017-12-31 | $1.00 10-K · filed 2019-03-29 | |||
| 2017-09-30 | $1.00 10-Q · filed 2017-11-13 | |||
| 2017-06-30 | $1.00 10-Q · filed 2017-08-08 | |||
| 2016-12-31 | $0.26 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |